Seribantumab is under clinical development by Elevation Oncology and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seribantumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Seribantumab (MM-121, SAR-256212) is under development for the treatment of NRG1 gene fusion positive solid tumors including pancreatic cancer, lung cancer, head and neck cancer, breast cancer, kidney cancer, colorectal cancer, bladder cancer, ovarian cancer, sarcoma, gallbladder cancer, bile duct cancer, esophageal cancer, uterine cancer and prostate cancer. The drug candidate is administered through intravenous route. MM-121 is a fully human IgG2 antibody that targets human epidermal growth factor receptor 3 (ErbB3 or EGFR3).
It was also under development for HER2 negative metastatic or triple negative breast cancer, platinum-resistant/refractory ovarian cancer, fallopian tube cancer, peritoneal cancer, endometrial cancer, squamous cell head and neck cancer (second line), non-small cell lung cancer, and epithelial ovarian cancer.
Elevation Oncology overview
Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients. Elevation Oncology is headquartered in New York City, New York, the US.
For a complete picture of Seribantumab’s drug-specific PTSR and LoA scores, buy the report here.